[Erythropoietin and hypertension].
Hypertension is one of the adverse effects associated with recombinant human erythropoietin (rHuEPO) therapy for anaemia in hemodialysed patients. The incidence of hypertension is reported to be 10-15%. The exact mechanism of rHuEPO-induced hypertension has not been fully elucidated, although in this paper several theories have been presented.